RedHill Biopharma Ltd.

www.redhillbio.com/home/default.aspx

High-Tech Company
Public Company

(NASDAQ CM: RDHL)

TECH VERTICALS

Biotechnology, Life Sciences, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	Revenue Growth
Established	2009
Number of Employees	50
Employees in Israel	16
Reg. Number:	abCDe

DESCRIPTION

RedHill Biopharma is a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal and infectious diseases.

TECHNOLOGY

RedHill commercializes and promotes several gastrointestinal products in the U.S. RedHill’s development pipeline includes several drug candidates in advanced clinical development stages, addressing clear medical needs and aiming to relieve suffering and improve patient's quality of life.

Products and Phases

Product	Phase
RHB-102	Phase III
RHB-102 is a proprietary, oral, extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron. RHB-102 is being developed for several gastrointestinal indications: Gastroenteritis and Gastritis; IBS-D (diarrhea-predominant irritable bowel syndrome) and for chemotherapy and radiotherapy induced nausea and vomiting.
RHB-104	Phase III
RHB-104 is an orally-administered, all-in-one antibiotic combination therapy, with intracellular, antimycobacterial and anti-inflammatory properties. RHB-104 has completed a positive first Phase 3 study in Crohn’s disease, meeting its primary and key secondary endpoints, as well as a positive Phase 2a proof-of-concept study in relapsing remitting multiple sclerosis.
Talicia®	FDA Approved
TALICIA is a U.S. FDA-approved oral, all-in-one capsule containing omeprazole, amoxicillin, and rifabutin that is indicated for the treatment of Helicobacter pylori infection in adults.
Aemcolo® (rifamycin)	FDA Approved
AEMCOLO is a rifamycin antibacterial indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in adults. AEMCOLO is not recommended for use in patients with diarrhea complicated by fever and/or bloody stool or due to pathogens other than noninvasive strains of E. coli.
RHB-204	Phase III
RHB-204 is a fixed-dose oral capsule undergoing a U.S. Phase 3 clinical study to evaluate its efficacy as a first-line, stand-alone treatment of pulmonary Nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC).
Opaganib	Phase III
Opaganib is a first-in-class new chemical entity with anti-inflammatory, anti-cancer and antiviral activity, under development for multiple indications. Opaganib is an orally-administered, selective inhibitor of sphingosine kinase-2 (SK2), a lipid kinase with multiple cellular functions - potentially inhibiting tumor growth, pathological inflammation, and viral replication.
RHB-107	Phase III
RHB-107 (INN: upamostat) (formerly MESUPRON) is a first-in-class, once-daily, orally-administered, potent inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Patients suffering from: Helicobacter pylori infection, Crohn's disease, gastroenteritis, gastritis, IBS-D, acute enterocolitis, chronic diarrhea and loose stools, Cholangiocarcinoma, travelers’ diarrhea, NTM disease, prostate cancer and other oncology, inflammatory and gastrointestinal diseases.

	BUSINESS MODEL
	B2C

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Law Firm
abC Defghij	Accounting Firm

REMARKS

Date

Remark

20/10/2025

RedHill announced the signing of a strategic partnership with Cumberland Pharmaceuticals, a specialty pharmaceuticals company with a strong gastrointestinal market presence, whereby Cumberland will invest $4m for a 30% ownership stake in RedHill's global Talicia business. The companies will share in the financial performance and operational support for the Talicia brand with RedHill retaining 70% ownership and joint control. All other aspects of RedHill's business remain unchanged. RedHill and Cumberland have also entered into a U.S. Talicia co-commercialization agreement with an equal sharing of the product's net revenues.

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	21 Haarbaa St.
City	Tel Aviv
Country	Israel
Zip	6473921

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Raleigh, United States

Address	8311 Brier Creek Parkway, Suite 105-161
City	Raleigh
State/Province	NC
Country	United States
Zip	27617

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Dror Ben-Asher	CEO & Co-Founder	ProSeed (CEO)
Mr. Razi Ingber	CFO
Dr. Reza Fathi	SVP, R&D	XTL (Director of Research Operations)
Mr. Gilead Raday	COO	Sepal Pharma (CEO)
Mr. Adi Frish	Chief Corporate & Business Development Officer	Xylo (VP, Business Developement)
Mr. Guy Goldberg	Chief Business Officer
Dr. June Almenoff	Chief Medical Officer
Ms. Michelle Snelling	VP, HR

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	CEO & Co-Founder, Redhill Biopharma
abC Defghij	Board Member	President, RedHill Biopharma Inc.
abC Defghij	Board Member	Senior Executive, Lifeline Scientific
abC Defghij	Board Member	Director, Minerva Biotechnologies
abC Defghij	Board Member	Co-Founder, Ethrog Biotechnologies
abC Defghij	Board Member	Co-Founder & Manager of Danbar Group
abC Defghij	Board Member	Founder, Ayala Pharmaceuticals

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Apr. 02, 2024	Thirteenth Public Offering		abCDe	abCDe	Registered Direct Offering of American Depositary Shares (ADSs) and warrants
Jan. 26, 2024	Twelfth Public Offering	NASDAQ CM	abCDe	abCDe	Registered Direct Offering
Jul. 25, 2023	Eleventh Public Offering		abCDe	abCDe	Registered Direct Offering and Warrant Exercise
Apr. 03, 2023	Tenth Public Offering	NASDAQ CM	abCDe	abCDe	Registered Direct Offering
Dec. 02, 2022	Ninth Public Offering	NASDAQ CM	abCDe	abCDe	ADS shares and warrants
May. 09, 2022	Eighth Public Offering		abCDe	abCDe	Registered Direct Offering; ADS shares and warrants
Nov. 19, 2021	Seventh Public Offering	NASDAQ CM	abCDe	abCDe
Dec. 06, 2018	Sixth Public Offering	NASDAQ CM	abCDe	abCDe
Aug. 14, 2018	Fifth Public Offering	NASDAQ CM	abCDe	abCDe	ADS Offering.
Dec. 27, 2016	Fourth Public Offering	NASDAQ CM	abCDe	abCDe	Through ADS.
Jul. 17, 2015	Third Public Offering	NASDAQ CM	abCDe	abCDe
Feb. 10, 2015	Second Public Offering	NASDAQ CM	abCDe	abCDe
Dec. 27, 2012	Listing	NASDAQ CM	abCDe	abCDe	Through American Depositary Shares (ADRs). Registration and listing process did not include capital raising.
Feb. 03, 2011	IPO	TASE	abCDe	abCDe	02/2020: Delisted from TASE.

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Oct. 20, 2025

Revenue Growth

abCDe

PIPE

Mar. 08, 2023

Initial Revenues

abCDe

PIPE

Nov. 08, 2021

Initial Revenues

abCDe

PIPE

Oct. 18, 2019

Initial Revenues

abCDe

PIPE

Dec. 27, 2016

R&D

abCDe

PIPE

Jan. 22, 2014

R&D

abCDe

PIPE

Dec. 30, 2013

R&D

abCDe

PIPE

Dec. 04, 2012

R&D

abCDe

First Round - Extended

Nov. 03, 2010

R&D

abCDe

First Round

Sep. 12, 2010

R&D

abCDe

Seed

Sep. 01, 2009

Seed

abCDe

Last Updated:	abCDe
IVC Number:	abCDe